AGONISTS AND RECEPTORS

Key Concepts

  • Definitions and concepts to understand by the end of the lecture:

    • Terms to define:

    • Ligands

    • Receptors

    • Receptor definition process

    • Dose-response relationships

    • Quantitative concepts:

    • Kd (Dissociation constant)

    • Bmax (Maximal binding capacity)

    • IC50 (Inhibitory Concentration 50)

    • EC50 (Effective Concentration 50)

    • Mechanism of partial agonists for different receptor types

    • Definitions of:

    • Agonists

    • Partial agonists

    • Intrinsic activity

    • Concepts of efficacy and potency

RECEPTORS

  • Key Quote: "Drugs do not act unless bound" (Paul Ehrlich, 1913)

  • Role of receptors in pharmacology:

    • Some drugs inhibit enzymes (e.g., Aspirin)

    • Majority bind to receptors

LIGANDS

  • Definition:

    • A ligand is a chemical that specifically binds to a receptor.

    • Agonist: A ligand that binds to a receptor and causes a biological response.

    • Antagonist: A ligand that binds to a receptor but has no effect; it prevents other ligands from binding.

BIOLOGICAL RELEVANCE

  • Receptors have normal physiological roles, often as hormone or neurotransmitter receptors.

    • The body produces a natural ligand, usually acting as an agonist.

    • Drugs are selective for certain receptors, and receptors are selective for specific tissues.

LIGAND-RECEPTOR INTERACTIONS

  • Analogy to enzyme-substrate interactions:

    • Lock: Enzyme/receptor

    • Key: Substrate/hormone/drug

CHARACTERISTICS OF A RECEPTOR

  • Receptors were first defined in the early 1900s by Paul Ehrlich.

  • Properties of receptors:

    • Structural and steric specificity

    • Expressed in select tissues

    • Saturable and finite (i.e., limited number of binding sites)

    • High affinity for its endogenous ligand at physiological concentrations

    • Upon binding to the endogenous ligand, biochemical events are triggered.

RECEPTOR-RESPONSE PATHWAY

  • Phases of receptor activation:

    1. Reception - Ligand binding

    2. Transduction - Signal transduction pathway activation

    3. Response - Activation of cellular responses

RECEPTOR SPECIFICITY

  • Receptors demonstrate specificity for their ligands:

    • Example: Adrenaline (epinephrine) specifically binds to β1-adrenoreceptors in the heart, increasing heart rate and force of contraction.

    • Example: Dopamine acts on dopamine receptors in the brain to deliver reward signals and regulate movement.

TISSUE SPECIFICITY

  • Angiotensin, a peptide hormone, Reacts with Angiotensin (AT) receptors primarily in the vascular smooth muscle and kidney epithelium.

    • The action is selective and does not affect other smooth muscle types or intestinal epithelium.

THE DOSE-RESPONSE RELATIONSHIP

  • The relationship between tissue responses and receptor occupancy by agonists is typically directly proportional.

  • Fundamental graphical representation: Dose-response curve.

A DOSE-RESPONSE CURVE

  • Example parameters:

    • Y-axis: Heart rate (beats per minute)

    • X-axis: [Adrenaline]

    • Curve representation:

    • Shows how changes in drug dosage correlate with biological response.

EC50

  • Definition:

    • The Effective Concentration 50 (EC50) is the concentration of an agonist that produces 50% of its maximum response.

LOGARITHM

  • Mathematical concepts concerning logarithmic scale:

    • Logarithmically scaling concentration aids in understanding dose-response relationships.

    • Examples of logs:

    • ( ext{Log}_{10}10 = 1)

    • ( ext{Log}_{10}100 = 2)

    • ( ext{Log}_{10}1000 = 3)

DRUG-RECEPTOR INTERACTIONS

  • Functional studies: Measures the response of tissue to drugs.

    • Cannot detect antagonists directly, only indirectly through effects.

  • Binding studies:

    • Measures radiolabeled drug binding to tissues—applicable for agonists and antagonists but does not assess functional responses.

LAW OF MASS ACTION

  • Concepts:

    • Drugs/agonists bind specifically to receptors, with limited receptor numbers present across various tissues.

    • Binding saturation occurs at certain concentrations.

    • States include:

    • All receptors are equally accessible to ligands.

    • Receptors can exist as free or bound states.

    • Binding is reversible and does not change the receptor or ligand properties.

RADIOLABEL BINDING

  • Example of experimental context using radiolabeled drugs to study receptor binding dynamics.

BINDING STUDIES

  • Components involved:

    • Radiolabeled drug

    • Tissue

    • Assessing free and bound states of binding.

BINDING ISOTHERM

  • Analysis of binding dynamics:

    • Represents the relationship between the concentration of radioligand and binding outcomes.

    • The specific binding curve resembles a Dose-response curve.

QUANTIFICATION OF DRUG ACTION

  • Interpretation of dose-response curves aligns with Michaelis-Menten kinetics, integrated into the Langmuir equation.

  • Typically presented as Log Dose-Response curves, facilitating measurement of drug affinity (Kd) and maximal effect (E{max}).

QUANTITATIVE DRUG ACTION

  • Underlying assumptions:

    • Drug interacts reversibly with receptor systems.

    • Effects are proportional to the number of receptors occupied by the agonist.

    • Interaction model:

    • D + R \rightleftharpoons DR \rightarrow E, where D is the drug, R is the receptor, DR is the drug-receptor complex, and E is the effect.

REVERSIBLE BINDING

  • Key parameters involved:

    • k_1: Rate of ligand binding to receptor

    • k_2: Rate of separation from receptor

  • Equations for concentration definitions:

    • [D] + [R] \rightleftharpoons [DR]

    • [D] - Free drug concentration, [R] - Concentration of receptors

DISSOCIATION CONSTANT (K_D)

  • At equilibrium, K_D represents the dissociation constant, defined as:

    • K_D = \frac{[D][R]}{[DR]}

CALCULATING K

  • Identifies the rate constants when all receptors are occupied, defined as R_t.

  • The maximum response is E_{max}.

  • Key relationship: If E=50%, then K_D = [D].

POTENCY

  • Potency is a measure of drug activity relative to the dose required to produce a specific effect intensity.

  • Correlates directly with affinity, which can be derived from dose-response analysis.

INTRINSIC ACTIVITY / EFFICACY

  • Not all agonists achieve maximum potential response; these are termed partial agonists.

  • Intrinsic activity (\alpha) reflects the ability to produce a response:

    • \alpha=1: Full agonist

    • 1 > \alpha > 0: Partial agonist

    • \alpha=0: Antagonist

  • Partial agonists bind to all receptors but exhibit lower probability of generating a response compared to full agonists.

INTRINSIC ACTIVITY VS POTENCY

  • Example comparison:

    • Drug A and Drug B show the same efficacy.

    • Drug A and Drug C are equipotent with the same EC_{50}.

    • At identical doses, Drug A produces a more substantial response than B or C.

CLINICAL EXAMPLE: VARENICLINE

  • Discusses the pharmacological action of varenicline in relation to nicotine and its potential implications on dopamine activity through nicotine receptors.

SPARE RECEPTORS

  • Concept of spare receptors and their relation to drug effectiveness

    • Existence of spare receptors allows drugs to achieve maximum efficacy even when not all receptors are saturated.

    • Visualization of the relationship can be represented on a graph showing percent drug effect against receptor occupancy.

SUMMARY

  • Differentiation between:

    • Agonists and Partial Agonists based on binding and resultant biological response relative to natural ligands.

    • Concentrations of agonists determine the degree of signaling and biological response, with implications for understanding drug efficacy, potency, and therapeutic applications.